Diag-Nose.io, a pioneering biotech company, has closed an oversubscribed seed funding round of $2 million. The funding will support the development of its innovative RhinoMAP™ platform and ABEL Microsampler™ technology, aimed at transforming respiratory disease management.
Who to call at Diag-Nose.io, and when
A new round usually means Diag-Nose.io is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Diag-Nose.io raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Diag-Nose.io, from your own LinkedIn network
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Diag-Nose.io
Location
Bethlehem, Pennsylvania, United States
About
Diag-Nose.io is a biotechnology company founded in 2020, focusing on precision diagnostic and drug discovery solutions for chronic respiratory diseases. Their technology integrates advanced proteomics, computational biology, and AI to enhance treatment prescription and accelerate new therapy development. The flagship platform, RhinoMAP™, aims to predict respiratory disease activity and monitor treatment efficacy. Diag-Nose.io's innovative approach seeks to transform respiratory healthcare through data-driven personalized care.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Diag-Nose.io raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BethlehemBiotechnologyHealth CareArtificial IntelligenceTherapeuticsHealth Diagnostics